Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection
Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009–2012, 39...
Saved in:
Published in | Pediatric blood & cancer Vol. 62; no. 9; pp. 1543 - 1549 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.09.2015
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1545-5009 1545-5017 |
DOI | 10.1002/pbc.25511 |
Cover
Abstract | Background
Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection.
Material and Methods
From 2009–2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI.
Results
Median age at diagnosis was 30 months [range 2–191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN‐amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post‐surgical histology lost more IDRFs (median: 1[0–9]) than patients with ganglioneuroblastoma (median: 0[0–4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028).
Conclusion
IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543–1549. © 2015 Wiley Periodicals, Inc. |
---|---|
AbstractList | Background
Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection.
Material and Methods
From 2009–2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI.
Results
Median age at diagnosis was 30 months [range 2–191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN‐amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post‐surgical histology lost more IDRFs (median: 1[0–9]) than patients with ganglioneuroblastoma (median: 0[0–4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028).
Conclusion
IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543–1549. © 2015 Wiley Periodicals, Inc. Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028). IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n=20), paravertebral (n=13) and perivascular (n=6). INRGSS stages were L2 (n=13), M (n=25) and Ms (n=1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P<0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P=0.002), independent of the primary tumor location (P=0.73), although the number was higher in patients with left versus right adrenal locations (P=0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P<0.001). The completeness of resection was related only to the number of preoperative IDRFs (P=0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015; 62:1543-1549. Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n=20), paravertebral (n=13) and perivascular (n=6). INRGSS stages were L2 (n=13), M (n=25) and Ms (n=1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P<0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P=0.002), independent of the primary tumor location (P=0.73), although the number was higher in patients with left versus right adrenal locations (P=0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P<0.001). The completeness of resection was related only to the number of preoperative IDRFs (P=0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543-1549. © 2015 Wiley Periodicals, Inc. |
Author | Schleiermacher, Gudrun Canale, Sandra Minard-Colin, Véronique Elie, Caroline Michon, Jean Le Cossec, Chloé Brisse, Hervé J Galmiche-Rolland, Louise Valteau-Couanet, Dominique Irtan, Sabine Sarnacki, Sabine |
Author_xml | – sequence: 1 givenname: Sabine surname: Irtan fullname: Irtan, Sabine email: Correspondence to: Sabine Irtan, Service de Chirurgie Pédiatrique Viscérale - Sorbonnes Universités, UPMC Univ Paris 06, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, 26, avenue Dr Arnold Netter, 75012 PARIS, France. , sabine.irtan@gmail.com organization: Pediatric surgery department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France – sequence: 2 givenname: Hervé J surname: Brisse fullname: Brisse, Hervé J organization: Radiology department, Curie institute, Paris, France – sequence: 3 givenname: Véronique surname: Minard-Colin fullname: Minard-Colin, Véronique organization: Pediatric Oncology department, Gustave- Roussy Institute, Paris, France – sequence: 4 givenname: Gudrun surname: Schleiermacher fullname: Schleiermacher, Gudrun organization: Pediatric Oncology department, Curie institute, Paris, France – sequence: 5 givenname: Louise surname: Galmiche-Rolland fullname: Galmiche-Rolland, Louise organization: Pathology department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France – sequence: 6 givenname: Chloé surname: Le Cossec fullname: Le Cossec, Chloé organization: Biostatistics department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France – sequence: 7 givenname: Caroline surname: Elie fullname: Elie, Caroline organization: Biostatistics department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France – sequence: 8 givenname: Sandra surname: Canale fullname: Canale, Sandra organization: Radiology department, Gustave-Roussy Institute, Paris, France – sequence: 9 givenname: Jean surname: Michon fullname: Michon, Jean organization: Pediatric Oncology department, Curie institute, Paris, France – sequence: 10 givenname: Dominique surname: Valteau-Couanet fullname: Valteau-Couanet, Dominique organization: Pediatric Oncology department, Gustave- Roussy Institute, Paris, France – sequence: 11 givenname: Sabine surname: Sarnacki fullname: Sarnacki, Sabine organization: Pediatric surgery department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25820608$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kctu1DAUhi1URC-w4AWQJTawSGs7cZwsIYJSqYKKi1haHud46mlip7ZTmLfiEfEwMxWqYGXr6Pv_c_mP0YHzDhB6TskpJYSdTQt9yjin9BE6orziBSdUHNz_SXuIjmNcZbQmvHmCDhlvGKlJc4R-XYxqCUUPxjrocbDxBhulkw9YxQgxjuAS9gY7mINfgrMap3n0IWJlEoRc96pfzXcqY_oaRp-uIahpjW3EcwQzD9hksylAb3WybomtS0EVfspYsnfwd89s6nqcHbD24zRAApdH2LQPECHLvXuKHhs1RHi2e0_Qt_fvvnYfistP5xfdm8tCVy2hBVe1UcwQCpS3LWMlp0z0JRV1LVjFWAOlolrrssn30ZVQ-TZC5SpXbW0WtDxBr7a-U_C3M8QkRxs1DIPKG89RUkFaKmhL2oy-fICu_Bxcnk7Sum0qQhq-MXyxo-bFCL2cgh1VWMt9Fhk42wI6-BgDGKltUpud873sICmRm7RlTlv-STsrXj9Q7E3_xe7cf9gB1v8H5dXbbq8otgobE_y8V6hwI2tRCi6_fzyXXz5T0XX0SvLyNy0_ymk |
CitedBy_id | crossref_primary_10_1007_s00383_018_4241_5 crossref_primary_10_1016_j_jpedsurg_2024_162108 crossref_primary_10_1200_JCO_19_03117 crossref_primary_10_3892_ol_2022_13329 crossref_primary_10_1186_s12893_024_02508_x crossref_primary_10_1007_s00383_023_05477_z crossref_primary_10_1002_pbc_27670 crossref_primary_10_1007_s00431_023_04899_0 crossref_primary_10_1186_s12880_020_00503_1 crossref_primary_10_1186_s43055_020_00205_2 crossref_primary_10_4103_ijpm_ijpm_362_21 crossref_primary_10_1097_MPH_0000000000001607 crossref_primary_10_1186_s12887_017_0826_8 crossref_primary_10_1002_pbc_27955 crossref_primary_10_1002_pbc_26605 crossref_primary_10_1097_MOP_0000000000000439 crossref_primary_10_1002_pbc_31317 crossref_primary_10_12998_wjcc_v7_i12_1499 crossref_primary_10_1016_j_ijrobp_2018_11_041 crossref_primary_10_1016_j_jpedsurg_2021_04_030 crossref_primary_10_2214_AJR_20_25310 crossref_primary_10_1136_wjps_2022_000531 crossref_primary_10_1245_s10434_021_10381_8 crossref_primary_10_1007_s12519_019_00274_y crossref_primary_10_23736_S1824_4785_18_03031_5 crossref_primary_10_1002_pbc_31161 crossref_primary_10_1053_j_sempedsurg_2019_04_014 crossref_primary_10_1111_ans_19420 crossref_primary_10_1002_pbc_27867 crossref_primary_10_1007_s00383_020_04627_x crossref_primary_10_1186_s40644_020_00366_3 crossref_primary_10_1007_s00261_022_03596_0 crossref_primary_10_3389_fped_2021_761896 crossref_primary_10_3390_jcm12237297 crossref_primary_10_1007_s00383_020_04731_y crossref_primary_10_1136_wjps_2020_000129 crossref_primary_10_1016_j_jpedsurg_2019_02_040 crossref_primary_10_1007_s00247_020_04960_2 crossref_primary_10_1007_s00383_020_04696_y crossref_primary_10_3390_children10010089 crossref_primary_10_1097_MD_0000000000016752 crossref_primary_10_3390_uro1040028 crossref_primary_10_1016_j_sipas_2023_100195 crossref_primary_10_1007_s00247_016_3572_4 crossref_primary_10_1097_SLA_0000000000003947 crossref_primary_10_1007_s00383_022_05361_2 crossref_primary_10_1590_0102_6720201700020003 crossref_primary_10_2147_OTT_S324015 crossref_primary_10_1111_1759_7714_13277 crossref_primary_10_4103_ajps_ajps_152_21 crossref_primary_10_1016_j_jpedsurg_2016_02_069 crossref_primary_10_21682_2311_1267_2019_6_3_31_43 crossref_primary_10_1002_pbc_31218 crossref_primary_10_1007_s00383_016_3932_z crossref_primary_10_1089_lap_2016_0390 crossref_primary_10_1002_pbc_30724 crossref_primary_10_1016_j_clon_2021_10_014 crossref_primary_10_1002_cam4_3663 crossref_primary_10_1245_s10434_021_10386_3 crossref_primary_10_1002_pbc_29260 crossref_primary_10_1002_pbc_25585 |
Cites_doi | 10.1016/j.ejca.2008.09.016 10.1200/JCO.2000.18.3.477 10.1016/j.jpedsurg.2010.09.075 10.1016/j.molonc.2008.07.002 10.1148/radiol.11101352 10.1016/S0959-8049(97)00308-0 10.1200/JCO.2011.35.9570 10.1002/pbc.21343 10.1200/JCO.2008.17.5877 10.1016/0022-3468(95)90576-6 10.1200/JCO.1993.11.8.1466 10.1055/s-0031-1280824 10.1200/JCO.2005.02.4661 10.1016/j.jpedsurg.2003.11.028 10.1200/JCO.2012.45.9339 10.1007/s00383-012-3109-3 10.1200/JCO.2000.18.1.18 10.1055/s-2002-36952 10.1200/JCO.1988.6.12.1874 10.1200/JCO.2008.16.6876 10.1016/S0022-3468(96)90486-8 |
ContentType | Journal Article |
Copyright | 2015 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2015 Wiley Periodicals, Inc. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7TO 8FD FR3 H94 K9. P64 RC3 |
DOI | 10.1002/pbc.25511 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE Neurosciences Abstracts Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1545-5017 |
EndPage | 1549 |
ExternalDocumentID | 3754264441 25820608 10_1002_pbc_25511 PBC25511 ark_67375_WNG_SR17CC1P_5 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OB 1OC 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABPPZ ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RX1 RYL SUPJJ SV3 TEORI UB1 UDS V2E W8V W99 WBKPD WHWMO WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7TO 8FD FR3 H94 K9. P64 RC3 |
ID | FETCH-LOGICAL-c4901-5a6fa2f01e15992235127d31766724228e3a1ccc38500c47a0267a8e35a96fb13 |
IEDL.DBID | DR2 |
ISSN | 1545-5009 |
IngestDate | Sun Aug 24 04:01:52 EDT 2025 Fri Jul 25 07:29:45 EDT 2025 Thu Apr 03 07:04:50 EDT 2025 Thu Apr 24 22:57:27 EDT 2025 Tue Jul 01 03:53:06 EDT 2025 Wed Aug 20 07:24:36 EDT 2025 Sun Sep 21 06:21:39 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | neuroblastoma surgical complications IDRF |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4901-5a6fa2f01e15992235127d31766724228e3a1ccc38500c47a0267a8e35a96fb13 |
Notes | ark:/67375/WNG-SR17CC1P-5 istex:C63008FF01659A5D14096373D61D994F47AD07C7 ArticleID:PBC25511 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 25820608 |
PQID | 1698400851 |
PQPubID | 1036357 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1709171909 proquest_journals_1698400851 pubmed_primary_25820608 crossref_citationtrail_10_1002_pbc_25511 crossref_primary_10_1002_pbc_25511 wiley_primary_10_1002_pbc_25511_PBC25511 istex_primary_ark_67375_WNG_SR17CC1P_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2015 |
PublicationDateYYYYMMDD | 2015-09-01 |
PublicationDate_xml | – month: 09 year: 2015 text: September 2015 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Glenview |
PublicationTitle | Pediatric blood & cancer |
PublicationTitleAlternate | Pediatr Blood Cancer |
PublicationYear | 2015 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289-294. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008; 50:965-969. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 2000; 18:18-26. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier- Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau- Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S. Mol Oncol 2008; 2:261-271. Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, Cheung NK, La Quaglia MP. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011; 46:103-107. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39:412-417. Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-1437. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:298-303. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6:1874-1881. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18:477-486. Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752-758. Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011; 29:4358-4364. Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23:8483-8489. Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg 2011; 21:314-317. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261:243-257. Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice. Pediatr Surg Int 2012; 28:953-959. De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27:1034-1040. Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009; 45:90-98. Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12:402-409. Powis MR, Imeson JD, Holmes SJ. The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group. J Pediatr Surg 1996; 31:516-519. 2009; 45 1995; 30 2000; 18 1997; 33 2004; 39 1993; 11 1988; 6 2002; 12 2013; 31 2011; 21 2011; 46 2012; 28 2008; 50 2011; 261 2008; 2 2011; 29 2009; 27 2005; 23 1996; 31 e_1_2_6_21_1 e_1_2_6_10_1 e_1_2_6_20_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_19_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_3_1 e_1_2_6_11_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_22_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 |
References_xml | – reference: Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23:8483-8489. – reference: Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752-758. – reference: Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261:243-257. – reference: De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27:1034-1040. – reference: Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier- Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau- Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S. Mol Oncol 2008; 2:261-271. – reference: Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18:477-486. – reference: Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:298-303. – reference: Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12:402-409. – reference: Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-1437. – reference: Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477. – reference: La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39:412-417. – reference: Powis MR, Imeson JD, Holmes SJ. The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group. J Pediatr Surg 1996; 31:516-519. – reference: Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6:1874-1881. – reference: Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009; 45:90-98. – reference: Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011; 29:4358-4364. – reference: Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289-294. – reference: Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 2000; 18:18-26. – reference: Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, Cheung NK, La Quaglia MP. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011; 46:103-107. – reference: Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice. Pediatr Surg Int 2012; 28:953-959. – reference: Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg 2011; 21:314-317. – reference: Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008; 50:965-969. – volume: 31 start-page: 516 year: 1996 end-page: 519 article-title: The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group publication-title: J Pediatr Surg – volume: 27 start-page: 1034 year: 2009 end-page: 1040 article-title: Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without gene amplification publication-title: J Clin Oncol – volume: 30 start-page: 289 year: 1995 end-page: 294 article-title: Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems publication-title: J Pediatr Surg – volume: 11 start-page: 1466 year: 1993 end-page: 1477 article-title: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment publication-title: J Clin Oncol – volume: 21 start-page: 314 year: 2011 end-page: 317 article-title: Significance of image‐defined risk factors for surgical complications in patients with abdominal neuroblastoma publication-title: Eur J Pediatr Surg – volume: 27 start-page: 298 year: 2009 end-page: 303 article-title: The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report publication-title: J Clin Oncol – volume: 23 start-page: 8483 year: 2005 end-page: 8489 article-title: Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group publication-title: J Clin Oncol – volume: 31 start-page: 752 year: 2013 end-page: 758 article-title: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis publication-title: J Clin Oncol – volume: 33 start-page: 1430 year: 1997 end-page: 1437 article-title: Neuroblastoma publication-title: Eur J Cancer – volume: 18 start-page: 18 year: 2000 end-page: 26 article-title: Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study publication-title: J Clin Oncol – volume: 18 start-page: 477 year: 2000 end-page: 486 article-title: Favorable biology and outcome of stage IV‐S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study publication-title: J Clin Oncol – volume: 6 start-page: 1874 year: 1988 end-page: 1881 article-title: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma publication-title: J Clin Oncol – volume: 28 start-page: 953 year: 2012 end-page: 959 article-title: Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice publication-title: Pediatr Surg Int – volume: 261 start-page: 243 year: 2011 end-page: 257 article-title: Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project publication-title: Radiology – volume: 45 start-page: 90 year: 2009 end-page: 98 article-title: Management and outcome of stage 3 neuroblastoma publication-title: Eur J Cancer – volume: 29 start-page: 4358 year: 2011 end-page: 4364 article-title: Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age publication-title: J Clin Oncol – volume: 46 start-page: 103 year: 2011 end-page: 107 article-title: Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries publication-title: J Pediatr Surg – volume: 50 start-page: 965 year: 2008 end-page: 969 article-title: Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial publication-title: Pediatr Blood Cancer – volume: 2 start-page: 261 year: 2008 end-page: 271 article-title: ‐non‐amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S publication-title: Mol Oncol – volume: 12 start-page: 402 year: 2002 end-page: 409 article-title: The impact of surgical radicality on outcome in childhood neuroblastoma publication-title: Eur J Pediatr Surg – volume: 39 start-page: 412 year: 2004 end-page: 417 article-title: The impact of gross total resection on local control and survival in high‐risk neuroblastoma publication-title: J Pediatr Surg – ident: e_1_2_6_13_1 doi: 10.1016/j.ejca.2008.09.016 – ident: e_1_2_6_21_1 doi: 10.1200/JCO.2000.18.3.477 – ident: e_1_2_6_14_1 doi: 10.1016/j.jpedsurg.2010.09.075 – ident: e_1_2_6_20_1 doi: 10.1016/j.molonc.2008.07.002 – ident: e_1_2_6_6_1 doi: 10.1148/radiol.11101352 – ident: e_1_2_6_2_1 doi: 10.1016/S0959-8049(97)00308-0 – ident: e_1_2_6_22_1 doi: 10.1200/JCO.2011.35.9570 – ident: e_1_2_6_18_1 doi: 10.1002/pbc.21343 – ident: e_1_2_6_7_1 doi: 10.1200/JCO.2008.17.5877 – ident: e_1_2_6_12_1 doi: 10.1016/0022-3468(95)90576-6 – ident: e_1_2_6_3_1 doi: 10.1200/JCO.1993.11.8.1466 – ident: e_1_2_6_19_1 doi: 10.1055/s-0031-1280824 – ident: e_1_2_6_9_1 doi: 10.1200/JCO.2005.02.4661 – ident: e_1_2_6_16_1 doi: 10.1016/j.jpedsurg.2003.11.028 – ident: e_1_2_6_15_1 doi: 10.1200/JCO.2012.45.9339 – ident: e_1_2_6_17_1 doi: 10.1007/s00383-012-3109-3 – ident: e_1_2_6_8_1 doi: 10.1200/JCO.2000.18.1.18 – ident: e_1_2_6_10_1 doi: 10.1055/s-2002-36952 – ident: e_1_2_6_4_1 doi: 10.1200/JCO.1988.6.12.1874 – ident: e_1_2_6_5_1 doi: 10.1200/JCO.2008.16.6876 – ident: e_1_2_6_11_1 doi: 10.1016/S0022-3468(96)90486-8 |
SSID | ssj0026058 |
Score | 2.364903 |
Snippet | Background
Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined... Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added... Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1543 |
SubjectTerms | Abdominal Neoplasms - diagnostic imaging Abdominal Neoplasms - drug therapy Abdominal Neoplasms - epidemiology Abdominal Neoplasms - pathology Abdominal Neoplasms - surgery Adolescent Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Child Child, Preschool Combined Modality Therapy Cyclophosphamide - administration & dosage Diagnostic Imaging - methods Etoposide - administration & dosage Female Ganglioneuroblastoma - diagnostic imaging Ganglioneuroblastoma - drug therapy Ganglioneuroblastoma - epidemiology Ganglioneuroblastoma - pathology Ganglioneuroblastoma - surgery Hematology Hematopoietic Stem Cell Transplantation Humans IDRF Infant Kaplan-Meier Estimate Magnetic Resonance Imaging Male Neoadjuvant Therapy Neoplasm Staging Neoplasm, Residual neuroblastoma Neuroblastoma - diagnostic imaging Neuroblastoma - drug therapy Neuroblastoma - epidemiology Neuroblastoma - pathology Neuroblastoma - surgery Oncology Pediatrics Postoperative Complications - epidemiology Postoperative Complications - prevention & control Risk Assessment Risk Factors surgical complications Thoracic Neoplasms - diagnostic imaging Thoracic Neoplasms - drug therapy Thoracic Neoplasms - epidemiology Thoracic Neoplasms - pathology Thoracic Neoplasms - surgery Tomography, X-Ray Computed Treatment Outcome Vincristine - administration & dosage |
Title | Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection |
URI | https://api.istex.fr/ark:/67375/WNG-SR17CC1P-5/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.25511 https://www.ncbi.nlm.nih.gov/pubmed/25820608 https://www.proquest.com/docview/1698400851 https://www.proquest.com/docview/1709171909 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NbtQwEMetqpUQFyjfoQUZhBCXbDcfthtxgoVSkKiqQkUPSJbjD2lpd7PaJFLhxCP0YfpEPAkzdhIoKhLitvLOxs7O2PklmfmbkCdjazKWCxvbAu5N8txlsbLcxSw3WclhOeTKZ1vs8d3D_N0RO1ohz_tamKAPMTxww5nh12uc4Kqst36Jhi5KPQIe9nW9ScZRN__VwSAdhZjuy-CAEGIGINGrCo3TreGXF65Fa_i3nl4Gmhe51V94dq6Tz_2QQ77J8ahtypH-9oea43-e0zq51gEpfREi6AZZsfOb5Mr77pX7LXL-dgZLzo_vZ8Y6aDAUk9Fp2KaHqkHXk1aOem1MCMippk07q5Y19TuQQ3ulzJcWmL2hECOzrujrK53WtK2ta08ooDNdLLFTTMOmU3zkDH1WCxuUyX_vFQ47NxSOQX0-PFI_DAIHgKVUvk7jNjncef1xsht3Wz3EOgciiZniTqVunFjAqwKQBThEmAzVK0WKKmU2U4nWOtsGX-pcKNw4S0ErUwV3ZZLdIavzam7vEcocKzlQj7Xc5gVXyhkjnLHKCsTd7Yg8650udaeDjttxnMig4JxK8IL0XojI48F0EcQ_LjN66iNnsFDLY8yWE0x-2nsjPxwkYjJJ9iWLyGYfWrJbKGqZ8AJusZF7I_Jo-BqmOL63UeCfFmwEQJ0AcisicjeE5NBZylCAf4xn5QPr7-OU-y8n_sP9fzfdIFcBEFnIqdskq82ytQ8AwpryoZ9tPwE5CjE- |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3bbtQwEIZHVSsBN5wPKQUMQoibbDcH243EDawoW2hXVWlFbyrLiW1pafeg3UQCrngEHoYn4kmYcQ5QVCTE3crrjSfrsfPFnvkN8LRvTcJTaUOb4btJmrok1Fa4kKcmyQVOh0L7aIuRGB6lb4_58Qq8aHNhan2IbsGNRoafr2mA04L05i_V0Hle9BCIKbF3ze_PERIddOJRBOo-EQ4ZIeSIEq2uUD_e7H567mm0Rn_sp4tQ8zy5-kfP9jU4aY2uI05Oe1WZ94ovf-g5_u9dXYerDZOyl7UT3YAVO70Jl_aaXfdb8H1ngrPOj6_fjHVYYBjFo7P6pB6mO2lPNnPMy2OiT44LVlaT2WLJ_CHkWD7T5mOF2F4ydJNJk_f1mY2XrFpatI4hPbP5ghqlSGw2plVnbHM2t7U4-e-t4mWnhuE1mA-JJ_BHI8gAyqbyqRq34Wj79eFgGDanPYRFilASci2cjl0_skhYGVILoog0CQlYypiEymyio6Ioki3szCKVms7O0ljKdSZcHiV3YHU6m9p7wLjjuUDwsVbYNBNaO2OkM1ZbScS7FcDzttdV0Uih04kcZ6oWcY4V9oLyvRDAk67qvNb_uKjSM-86XQ29OKWAOcnVh9Eb9f4gkoNBtK94AButb6lmrliqSGT4lk3oG8Dj7msc5bR1o7F_KqwjkeskwlsWwN3aJ7vGYk4a_H26K-9Zf7dT7b8a-A_r_171EVweHu7tqt2d0bv7cAV5kdchdhuwWi4q-wCZrMwf-qH3EyYxNVw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFMetaZMmXrhfsg0wCCFe0jWJL4t4gkLZuFTVYGIPSJYT21LZ2kRtIgFPfAQ-DJ-IT8I5zgWGhoR4i5zT2KmP7V-Sc_4m5MHQmoQzaUObwrMJYy4JtRUu5MwkmYDpUGgfbTER-0fs5TE_XiOPu1yYRh-if-GGI8PP1zjAS-N2f4mGllk-AB7GvN4NJmCZRCI67LWjkNN9HhwgQsiBJDpZoWG82__0zGK0gf_rp_NI8yy4-pVnfIl86NrcBJycDOoqG-Rf_pBz_M-bukwutkRKnzQudIWs2cVVsvmm_eZ-jXw_mMOc8-PrN2MdFBiK0ei02aeH6l7YkxaOenFM8MhZTqt6XixX1G9BDuWFNh9rgPaKgpPM26yvz3S2ovXKuvqUAjvTcomVYhw2neE7Z6izKG0jTf57rXDZhaFwDeoD4hH7oRHYAMyl8oka18nR-Pm70X7Y7vUQ5gyQJORaOB27YWSBr1JgFgARaRKUr5QxypTZREd5nid70Jc5kxp3ztJQynUqXBYlN8j6oljYW4RyxzMB2GOtsCwVWjtjpDNWW4m8uxeQR12nq7wVQsf9OE5VI-EcK-gF5XshIPd707JR_zjP6KH3nN5CL08wXE5y9X7yQr09jORoFE0VD8hO51qqnSlWKhIpPGMj-AbkXn8axjh-uNHQPzXYSKA6CeiWBuRm45J9ZTFHBf4h3pV3rL-3U02fjvzB1r-b3iWb02dj9fpg8mqbXABY5E183Q5Zr5a1vQ1AVmV3_MD7CWsiNAs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Image-defined+risk+factor+assessment+of+neurogenic+tumors+after+neoadjuvant+chemotherapy+is+useful+for+predicting+intra-operative+risk+factors+and+the+completeness+of+resection&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Irtan%2C+Sabine&rft.au=Brisse%2C+Herv%C3%A9+J&rft.au=Minard-Colin%2C+V%C3%A9ronique&rft.au=Schleiermacher%2C+Gudrun&rft.date=2015-09-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1545-5009&rft.eissn=1545-5017&rft.volume=62&rft.issue=9&rft.spage=1543&rft.epage=1549&rft_id=info:doi/10.1002%2Fpbc.25511&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_SR17CC1P_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon |